Possible new treatment, pending Phase 3 study confirmation, for Dupuytren’s Disease reported by Oxford researchers.

Medical Mythbusting Commentary for May 17, 2022

Source:
Breakthrough In Treatment For Dupuytren’s Disease As Clinical Trial Shows Efficacy Of anti-TNF Drug

Reference:
Anti-tumour necrosis factor therapy for early-stage Dupuytren’s disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial

Bitnami